| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Greece | 33 | 2021 | 2091 | 2.16 | Why? |
| Roma | 2 | 2021 | 61 | 0.89 | Why? |
| Osteomyelitis | 2 | 2018 | 131 | 0.80 | Why? |
| Ribonucleosides | 1 | 2020 | 95 | 0.79 | Why? |
| Microscopic Polyangiitis | 1 | 2018 | 31 | 0.76 | Why? |
| Colchicine | 3 | 2020 | 730 | 0.75 | Why? |
| Rabies Vaccines | 1 | 2018 | 106 | 0.71 | Why? |
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 140 | 0.70 | Why? |
| Cervix Uteri | 2 | 2018 | 146 | 0.70 | Why? |
| Hepatitis A Virus, Human | 1 | 2017 | 12 | 0.69 | Why? |
| Anaplasmosis | 1 | 2017 | 21 | 0.68 | Why? |
| Acetylcysteine | 1 | 2020 | 255 | 0.68 | Why? |
| Anaplasma phagocytophilum | 1 | 2017 | 34 | 0.67 | Why? |
| Papillomavirus Infections | 4 | 2018 | 861 | 0.67 | Why? |
| Rabies | 1 | 2018 | 113 | 0.66 | Why? |
| Copper | 1 | 2020 | 288 | 0.64 | Why? |
| Cyclophosphamide | 1 | 2018 | 387 | 0.64 | Why? |
| Measles | 3 | 2018 | 608 | 0.62 | Why? |
| Hemoptysis | 1 | 2018 | 172 | 0.61 | Why? |
| Skin Diseases, Infectious | 1 | 2017 | 77 | 0.61 | Why? |
| Soft Tissue Infections | 1 | 2017 | 116 | 0.60 | Why? |
| Oseltamivir | 1 | 2019 | 583 | 0.59 | Why? |
| Hepatitis A | 1 | 2017 | 140 | 0.57 | Why? |
| Hyperbaric Oxygenation | 1 | 2018 | 268 | 0.56 | Why? |
| HLA-DR Antigens | 1 | 2017 | 563 | 0.54 | Why? |
| Lipopolysaccharide Receptors | 1 | 2017 | 357 | 0.54 | Why? |
| Post-Exposure Prophylaxis | 1 | 2018 | 472 | 0.53 | Why? |
| Urinary Tract Infections | 1 | 2019 | 534 | 0.52 | Why? |
| Nitric Oxide | 1 | 2020 | 769 | 0.50 | Why? |
| Travel | 5 | 2020 | 7220 | 0.50 | Why? |
| Macrophage Activation Syndrome | 1 | 2017 | 342 | 0.49 | Why? |
| Immunoglobulins | 1 | 2018 | 811 | 0.49 | Why? |
| Influenza B virus | 1 | 2019 | 815 | 0.49 | Why? |
| Recombination, Genetic | 1 | 2020 | 1265 | 0.49 | Why? |
| Papillomaviridae | 3 | 2018 | 404 | 0.49 | Why? |
| Immunity, Herd | 1 | 2020 | 1011 | 0.48 | Why? |
| Influenza, Human | 7 | 2020 | 10779 | 0.48 | Why? |
| Olfaction Disorders | 2 | 2020 | 3704 | 0.46 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.44 | Why? |
| Anti-Bacterial Agents | 6 | 2019 | 10083 | 0.43 | Why? |
| Interferons | 2 | 2020 | 2885 | 0.43 | Why? |
| Disease Notification | 1 | 2017 | 639 | 0.43 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2017 | 698 | 0.42 | Why? |
| Refugees | 2 | 2018 | 809 | 0.42 | Why? |
| Tumor Virus Infections | 1 | 2011 | 127 | 0.41 | Why? |
| Sexually Transmitted Diseases | 1 | 2018 | 694 | 0.41 | Why? |
| Recovery of Function | 1 | 2020 | 2461 | 0.41 | Why? |
| Disease Outbreaks | 10 | 2021 | 27595 | 0.40 | Why? |
| Influenza A virus | 2 | 2019 | 2234 | 0.39 | Why? |
| Uterine Cervical Neoplasms | 3 | 2017 | 842 | 0.39 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.39 | Why? |
| Seasons | 2 | 2019 | 4071 | 0.38 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.37 | Why? |
| Adenocarcinoma | 2 | 2017 | 651 | 0.37 | Why? |
| Autopsy | 1 | 2020 | 3495 | 0.37 | Why? |
| Respiratory Tract Infections | 4 | 2020 | 6817 | 0.37 | Why? |
| Immunization Programs | 2 | 2018 | 2006 | 0.35 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.35 | Why? |
| Cardiopulmonary Resuscitation | 1 | 2021 | 1876 | 0.34 | Why? |
| Methylprednisolone | 1 | 2018 | 2107 | 0.34 | Why? |
| Health Facilities | 2 | 2017 | 1230 | 0.33 | Why? |
| Models, Statistical | 3 | 2021 | 5312 | 0.33 | Why? |
| Carcinoma, Squamous Cell | 2 | 2017 | 902 | 0.32 | Why? |
| Shock, Septic | 1 | 2017 | 1313 | 0.32 | Why? |
| Measles virus | 2 | 2018 | 194 | 0.32 | Why? |
| Measles Vaccine | 2 | 2018 | 301 | 0.29 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.29 | Why? |
| Antiviral Agents | 7 | 2020 | 41703 | 0.29 | Why? |
| Phylogeny | 4 | 2020 | 13341 | 0.27 | Why? |
| Catheter-Related Infections | 2 | 2018 | 381 | 0.27 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.27 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.27 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.27 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2019 | 572 | 0.26 | Why? |
| Catheterization, Central Venous | 2 | 2018 | 458 | 0.25 | Why? |
| Cervical Intraepithelial Neoplasia | 2 | 2017 | 114 | 0.25 | Why? |
| Coronavirus Infections | 17 | 2020 | 253789 | 0.24 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.24 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.24 | Why? |
| Humans | 71 | 2021 | 930598 | 0.23 | Why? |
| Influenza Vaccines | 3 | 2017 | 2941 | 0.23 | Why? |
| Quarantine | 5 | 2021 | 18418 | 0.23 | Why? |
| Genome, Viral | 2 | 2020 | 13157 | 0.22 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.22 | Why? |
| Staphylococcus aureus | 2 | 2018 | 844 | 0.22 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 4 | 2015 | 8843 | 0.21 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2019 | 2984 | 0.21 | Why? |
| Biomedical Research | 1 | 2021 | 5270 | 0.21 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.20 | Why? |
| Dogs | 2 | 2018 | 2529 | 0.20 | Why? |
| Pilot Projects | 3 | 2021 | 5182 | 0.20 | Why? |
| Quasispecies | 1 | 2020 | 108 | 0.19 | Why? |
| Tubulin Modulators | 1 | 2020 | 126 | 0.19 | Why? |
| Ureaplasma | 1 | 2018 | 14 | 0.19 | Why? |
| Molecular Epidemiology | 2 | 2018 | 1638 | 0.19 | Why? |
| Hydroxylamines | 1 | 2020 | 182 | 0.19 | Why? |
| Forensic Medicine | 1 | 2020 | 116 | 0.19 | Why? |
| Aged | 24 | 2021 | 215776 | 0.19 | Why? |
| Vaccination | 5 | 2018 | 19050 | 0.19 | Why? |
| Salmonella enteritidis | 1 | 2017 | 10 | 0.18 | Why? |
| Salmonella Food Poisoning | 1 | 2017 | 13 | 0.18 | Why? |
| Infant, Newborn | 8 | 2021 | 23105 | 0.18 | Why? |
| Cytidine | 1 | 2020 | 219 | 0.18 | Why? |
| Public Health | 3 | 2021 | 16359 | 0.18 | Why? |
| Adult | 20 | 2021 | 244371 | 0.18 | Why? |
| Prodrugs | 1 | 2020 | 264 | 0.17 | Why? |
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 21 | 0.17 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.17 | Why? |
| Staphylococcal Skin Infections | 1 | 2017 | 32 | 0.17 | Why? |
| Hemorrhagic Fever Virus, Crimean-Congo | 1 | 2018 | 133 | 0.17 | Why? |
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2017 | 26 | 0.17 | Why? |
| Debridement | 1 | 2018 | 172 | 0.17 | Why? |
| Bites and Stings | 1 | 2018 | 91 | 0.17 | Why? |
| Reference Values | 1 | 2020 | 795 | 0.17 | Why? |
| Male | 27 | 2021 | 367725 | 0.16 | Why? |
| Chlamydia trachomatis | 1 | 2018 | 172 | 0.16 | Why? |
| Troponin | 2 | 2020 | 1058 | 0.16 | Why? |
| Drug Synergism | 1 | 2020 | 833 | 0.16 | Why? |
| Infant | 8 | 2021 | 30274 | 0.16 | Why? |
| Hemorrhagic Fever, Crimean | 1 | 2018 | 118 | 0.16 | Why? |
| Stroke | 4 | 2021 | 8839 | 0.16 | Why? |
| Animals, Domestic | 1 | 2018 | 272 | 0.16 | Why? |
| Lymphoma, B-Cell | 1 | 2018 | 166 | 0.16 | Why? |
| Pulmonary Alveoli | 2 | 2018 | 867 | 0.16 | Why? |
| HSP90 Heat-Shock Proteins | 1 | 2017 | 98 | 0.16 | Why? |
| Arbovirus Infections | 1 | 2018 | 104 | 0.16 | Why? |
| Child, Preschool | 9 | 2021 | 36283 | 0.16 | Why? |
| Kidney Function Tests | 1 | 2018 | 520 | 0.16 | Why? |
| Microarray Analysis | 1 | 2018 | 262 | 0.16 | Why? |
| Epidemiological Monitoring | 2 | 2020 | 3493 | 0.16 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.16 | Why? |
| HSP70 Heat-Shock Proteins | 1 | 2017 | 113 | 0.16 | Why? |
| Cross Infection | 2 | 2017 | 8675 | 0.15 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.15 | Why? |
| Fluorescent Antibody Technique | 1 | 2018 | 835 | 0.15 | Why? |
| Cell- and Tissue-Based Therapy | 1 | 2020 | 422 | 0.15 | Why? |
| Escherichia coli Infections | 1 | 2019 | 348 | 0.15 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.15 | Why? |
| Mandatory Reporting | 1 | 2017 | 140 | 0.15 | Why? |
| Pandemics | 18 | 2021 | 389249 | 0.15 | Why? |
| Helicobacter Infections | 1 | 2018 | 216 | 0.15 | Why? |
| Saudi Arabia | 3 | 2014 | 4423 | 0.14 | Why? |
| Survival Analysis | 2 | 2019 | 7592 | 0.14 | Why? |
| Helicobacter pylori | 1 | 2018 | 262 | 0.14 | Why? |
| Population Dynamics | 1 | 2018 | 378 | 0.14 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.14 | Why? |
| Prosthesis-Related Infections | 1 | 2018 | 302 | 0.14 | Why? |
| Epidemiologic Methods | 1 | 2018 | 392 | 0.14 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.14 | Why? |
| Prevalence | 6 | 2021 | 25773 | 0.14 | Why? |
| Communicable Disease Control | 4 | 2020 | 29620 | 0.13 | Why? |
| Histones | 1 | 2017 | 371 | 0.13 | Why? |
| Female | 22 | 2021 | 380317 | 0.13 | Why? |
| Hodgkin Disease | 1 | 2016 | 204 | 0.13 | Why? |
| Streptococcal Infections | 1 | 2017 | 255 | 0.13 | Why? |
| Adolescent | 11 | 2021 | 86841 | 0.13 | Why? |
| London | 1 | 2020 | 2166 | 0.13 | Why? |
| Polymorphism, Genetic | 1 | 2020 | 1074 | 0.12 | Why? |
| Thrombectomy | 2 | 2021 | 2272 | 0.12 | Why? |
| Ships | 1 | 2021 | 1046 | 0.12 | Why? |
| DNA Probes, HPV | 1 | 2011 | 1 | 0.12 | Why? |
| Autophagy | 1 | 2020 | 960 | 0.12 | Why? |
| Population Surveillance | 3 | 2018 | 4967 | 0.12 | Why? |
| Age Distribution | 2 | 2020 | 3567 | 0.12 | Why? |
| Gastroenteritis | 1 | 2017 | 489 | 0.12 | Why? |
| Infertility, Female | 1 | 2014 | 150 | 0.12 | Why? |
| Thrombolytic Therapy | 2 | 2021 | 2218 | 0.12 | Why? |
| Hemoglobins | 1 | 2018 | 958 | 0.12 | Why? |
| Papillomavirus E7 Proteins | 1 | 2011 | 20 | 0.12 | Why? |
| Epstein-Barr Virus Infections | 1 | 2016 | 366 | 0.12 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.12 | Why? |
| United Arab Emirates | 1 | 2014 | 704 | 0.12 | Why? |
| Oncogene Proteins, Viral | 1 | 2011 | 36 | 0.12 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.11 | Why? |
| Cats | 1 | 2018 | 1890 | 0.11 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.11 | Why? |
| Escherichia coli | 1 | 2019 | 1547 | 0.11 | Why? |
| Sentinel Surveillance | 1 | 2019 | 1093 | 0.11 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.11 | Why? |
| Ribavirin | 2 | 2018 | 1182 | 0.11 | Why? |
| Child | 9 | 2021 | 70012 | 0.11 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 3633 | 0.11 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.11 | Why? |
| Vaginal Smears | 1 | 2011 | 89 | 0.11 | Why? |
| Drug Therapy, Combination | 3 | 2020 | 7268 | 0.11 | Why? |
| Family Planning Services | 1 | 2014 | 236 | 0.11 | Why? |
| Animals, Wild | 1 | 2018 | 1028 | 0.11 | Why? |
| DNA, Viral | 2 | 2011 | 2521 | 0.11 | Why? |
| Inflammation | 4 | 2020 | 13255 | 0.11 | Why? |
| Adjuvants, Immunologic | 1 | 2020 | 1709 | 0.10 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.10 | Why? |
| Bronchoscopy | 1 | 2018 | 991 | 0.10 | Why? |
| Fertility | 1 | 2014 | 367 | 0.10 | Why? |
| Hospitals | 4 | 2020 | 11793 | 0.10 | Why? |
| Clostridium Infections | 1 | 2017 | 595 | 0.10 | Why? |
| Reproductive Techniques, Assisted | 1 | 2014 | 400 | 0.10 | Why? |
| Communicable Diseases, Imported | 1 | 2018 | 843 | 0.10 | Why? |
| Diarrhea | 3 | 2020 | 2743 | 0.10 | Why? |
| Cerebrovascular Disorders | 1 | 2018 | 1040 | 0.10 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.10 | Why? |
| Turkey | 1 | 2020 | 3937 | 0.10 | Why? |
| Cause of Death | 2 | 2020 | 4823 | 0.10 | Why? |
| Diagnosis, Differential | 3 | 2018 | 7220 | 0.10 | Why? |
| Women's Health | 1 | 2014 | 444 | 0.10 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.10 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.10 | Why? |
| Transients and Migrants | 2 | 2018 | 1468 | 0.10 | Why? |
| Home Care Services | 1 | 2020 | 1351 | 0.09 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.09 | Why? |
| Syndrome | 1 | 2014 | 1310 | 0.09 | Why? |
| Staphylococcal Infections | 1 | 2018 | 1099 | 0.09 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 877 | 0.09 | Why? |
| Rituximab | 1 | 2016 | 1096 | 0.09 | Why? |
| Public Health Administration | 1 | 2017 | 846 | 0.09 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 800 | 0.09 | Why? |
| Fatal Outcome | 2 | 2017 | 3438 | 0.09 | Why? |
| Guillain-Barre Syndrome | 1 | 2021 | 1495 | 0.09 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.09 | Why? |
| Epidemics | 2 | 2018 | 6407 | 0.09 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.08 | Why? |
| Interferon Type I | 1 | 2020 | 2789 | 0.08 | Why? |
| Genetic Variation | 2 | 2021 | 3919 | 0.08 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.08 | Why? |
| Heart Failure | 2 | 2018 | 6638 | 0.08 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.08 | Why? |
| Myocardial Infarction | 2 | 2018 | 3361 | 0.07 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.07 | Why? |
| Infection Control | 1 | 2014 | 23131 | 0.07 | Why? |
| Thrombocytopenia | 1 | 2018 | 2093 | 0.07 | Why? |
| Aged, 80 and over | 7 | 2020 | 88759 | 0.07 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.07 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.07 | Why? |
| Intensive Care Units | 3 | 2019 | 29594 | 0.07 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.07 | Why? |
| Health Policy | 2 | 2021 | 6242 | 0.07 | Why? |
| Tertiary Care Centers | 2 | 2020 | 8248 | 0.06 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.06 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Vulnerable Populations | 1 | 2018 | 3099 | 0.06 | Why? |
| Chiroptera | 1 | 2018 | 3530 | 0.06 | Why? |
| Brain | 1 | 2021 | 5133 | 0.06 | Why? |
| Models, Theoretical | 2 | 2019 | 6659 | 0.06 | Why? |
| Flow Cytometry | 1 | 2011 | 2393 | 0.06 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.06 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.06 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.06 | Why? |
| Immunosuppressive Agents | 2 | 2018 | 6331 | 0.06 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.06 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.06 | Why? |
| Laboratories | 1 | 2015 | 2858 | 0.06 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.06 | Why? |
| Virus Activation | 2 | 2017 | 480 | 0.06 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.06 | Why? |
| Spain | 1 | 2020 | 15545 | 0.06 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.06 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.05 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.05 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.05 | Why? |
| Animals | 4 | 2018 | 78931 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Reagent Kits, Diagnostic | 1 | 2011 | 2149 | 0.05 | Why? |
| Antineoplastic Agents | 1 | 2016 | 3550 | 0.05 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.05 | Why? |
| Binding Sites, Antibody | 1 | 2021 | 466 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Occupational Exposure | 1 | 2018 | 4742 | 0.05 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.05 | Why? |
| Rabeprazole | 1 | 2018 | 1 | 0.05 | Why? |
| Lansoprazole | 1 | 2018 | 7 | 0.05 | Why? |
| Oxazolidinones | 1 | 2018 | 49 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Bulgaria | 1 | 2018 | 117 | 0.05 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.05 | Why? |
| Rheumatic Diseases | 1 | 2014 | 2675 | 0.05 | Why? |
| Metronidazole | 1 | 2018 | 59 | 0.05 | Why? |
| Salicylates | 1 | 2018 | 48 | 0.05 | Why? |
| Arthroplasty, Replacement | 1 | 2018 | 47 | 0.05 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.05 | Why? |
| Minisatellite Repeats | 1 | 2017 | 53 | 0.04 | Why? |
| Bismuth | 1 | 2018 | 56 | 0.04 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2017 | 78 | 0.04 | Why? |
| DNA Viruses | 1 | 2020 | 184 | 0.04 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.04 | Why? |
| Human Papillomavirus DNA Tests | 1 | 2017 | 12 | 0.04 | Why? |
| Amoxicillin | 1 | 2018 | 98 | 0.04 | Why? |
| Ticks | 1 | 2018 | 107 | 0.04 | Why? |
| Clarithromycin | 1 | 2018 | 112 | 0.04 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.04 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.04 | Why? |
| RNA, Messenger | 1 | 2011 | 5131 | 0.04 | Why? |
| Databases, Bibliographic | 1 | 2018 | 182 | 0.04 | Why? |
| Gram-Positive Bacteria | 1 | 2018 | 230 | 0.04 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.04 | Why? |
| Fever | 1 | 2014 | 7795 | 0.04 | Why? |
| Environmental Pollution | 1 | 2020 | 344 | 0.04 | Why? |
| Glycopeptides | 1 | 2018 | 199 | 0.04 | Why? |
| Cephalosporins | 1 | 2018 | 250 | 0.04 | Why? |
| Lipopeptides | 1 | 2018 | 229 | 0.04 | Why? |
| Neoplasms, Second Primary | 1 | 2016 | 100 | 0.04 | Why? |
| Organometallic Compounds | 1 | 2018 | 206 | 0.04 | Why? |
| United Nations | 1 | 2018 | 367 | 0.04 | Why? |
| Critical Illness | 1 | 2019 | 17281 | 0.04 | Why? |
| Neoplasm Grading | 1 | 2017 | 400 | 0.04 | Why? |
| Doxycycline | 1 | 2018 | 307 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.04 | Why? |
| Computational Biology | 2 | 2021 | 4514 | 0.04 | Why? |
| Immunoglobulin Fab Fragments | 1 | 1998 | 556 | 0.04 | Why? |
| Virus Latency | 1 | 2017 | 251 | 0.04 | Why? |
| Fungi | 1 | 2018 | 471 | 0.04 | Why? |
| Weather | 1 | 2020 | 581 | 0.04 | Why? |
| Sequence Alignment | 1 | 2021 | 2109 | 0.03 | Why? |
| Angioplasty, Balloon, Coronary | 1 | 1998 | 365 | 0.03 | Why? |
| Benchmarking | 1 | 2018 | 627 | 0.03 | Why? |
| Fomites | 1 | 2020 | 709 | 0.03 | Why? |
| Contact Tracing | 1 | 2014 | 8448 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 13720 | 0.03 | Why? |
| Gram-Negative Bacteria | 1 | 2018 | 473 | 0.03 | Why? |
| Fertility Preservation | 1 | 2014 | 121 | 0.03 | Why? |
| Neuroimaging | 1 | 2021 | 1106 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.03 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| RNA Viruses | 1 | 2020 | 824 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Primary Prevention | 1 | 2018 | 778 | 0.03 | Why? |
| Endovascular Procedures | 1 | 2021 | 1302 | 0.03 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.03 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2014 | 12361 | 0.03 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.03 | Why? |
| Temperature | 1 | 2020 | 2305 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Waste Water | 1 | 2021 | 2185 | 0.03 | Why? |
| Gene Expression | 1 | 2020 | 3332 | 0.03 | Why? |
| Lung | 1 | 2018 | 31049 | 0.02 | Why? |
| Viral Proteins | 2 | 2021 | 7370 | 0.02 | Why? |
| Genes, Viral | 1 | 2015 | 1428 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2020 | 3788 | 0.02 | Why? |
| Cities | 1 | 2021 | 4937 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.02 | Why? |
| Open Reading Frames | 1 | 2015 | 1898 | 0.02 | Why? |
| Health Personnel | 1 | 2018 | 29646 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Hospitals, Pediatric | 1 | 2018 | 1792 | 0.02 | Why? |
| Viremia | 1 | 2014 | 1020 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Hemorrhage | 1 | 1998 | 3013 | 0.02 | Why? |
| Biosensing Techniques | 1 | 2020 | 2116 | 0.02 | Why? |
| Camelus | 1 | 2014 | 1425 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Congresses as Topic | 1 | 2014 | 1347 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Drug Combinations | 1 | 2014 | 3852 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Epithelial Cells | 1 | 2017 | 3508 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.02 | Why? |
| Magnetic Resonance Imaging | 1 | 2021 | 6551 | 0.02 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2011 | 2830 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.02 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Zoonoses | 1 | 2014 | 3034 | 0.01 | Why? |
| Lopinavir | 1 | 2014 | 4308 | 0.01 | Why? |
| Postoperative Complications | 1 | 1998 | 5861 | 0.01 | Why? |
| Ritonavir | 1 | 2014 | 4212 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 1998 | 8041 | 0.01 | Why? |
| Virus Shedding | 1 | 2014 | 5834 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Pregnancy | 1 | 2014 | 23879 | 0.01 | Why? |
| Stents | 1 | 1998 | 916 | 0.01 | Why? |
| Lung Diseases | 1 | 1998 | 2361 | 0.00 | Why? |
| Radiography, Thoracic | 1 | 1998 | 5486 | 0.00 | Why? |